The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.

@article{Choi2016TheDU,
  title={The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.},
  author={Jae-Lim Choi and Bo-Ram Kim and K. -S. Woo and Kyeong Hee Kim and J. Kim and M Kim and Jin Yeong Han},
  journal={Annals of clinical and laboratory science},
  year={2016},
  volume={46 5},
  pages={489-94}
}
BACKGROUND Clopidogrel is a widely used antiplatelet agent for dual antiplatelet therapy and metabolized by CYP2C19. The polymorphism of CYP2C19 is associated with the therapeutic effect of clopidogrel. METHODS A total of 119 patients diagnosed with acute coronary syndrome (ACS) and underwent percutaneous coronary intervention (PCI) with drug-eluting… CONTINUE READING